
















Medivation Announces Fourth Quarter and Year-End 2010 Financial Results Teleconference and Webcast on March, 16 2011


🞛 This publication is a summary or evaluation of another publication
SAN FRANCISCO, CA--(Marketwire - March 9, 2011) - Medivation, Inc. (
Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals interested in listening to the live call via webcast may do so by visiting [ http://www.medivation.com ]. A replay of the webcast will be available on the Company's website for 30 days.
About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at [ www.medivation.com ].